GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » 12-1 Month Momentum %

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) 12-1 Month Momentum % : 4.64% (As of May. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-29), Eucrates Biomedical Acquisition's 12-1 Month Momentum % is 4.64%.

The industry rank for Eucrates Biomedical Acquisition's 12-1 Month Momentum % or its related term are showing as below:

EUCRU's 12-1 Month Momentum % is not ranked
in the Diversified Financial Services industry.
Industry Median: 4.08 vs EUCRU: 4.64

Competitive Comparison of Eucrates Biomedical Acquisition's 12-1 Month Momentum %

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eucrates Biomedical Acquisition's 12-1 Month Momentum % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's 12-1 Month Momentum % falls into.



Eucrates Biomedical Acquisition  (NAS:EUCRU) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eucrates Biomedical Acquisition  (NAS:EUCRU) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Eucrates Biomedical Acquisition 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines